{"id":"NCT01085812","sponsor":"Forest Laboratories","briefTitle":"Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2011-10","completion":"2011-10","firstPosted":"2010-03-12","resultsPosted":"2020-01-13","lastUpdate":"2020-01-13"},"enrollment":734,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Depression","Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Levomilnacipran ER","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"2","type":"EXPERIMENTAL"},{"label":"1","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).","primaryOutcome":{"measure":"Time to Relapse (Days)","timeFrame":"24 Weeks","effectByArm":[{"arm":"Placebo","deltaMin":null,"sd":null},{"arm":"Levomilnacipran ER","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":35,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":734},"commonTop":["Headache","Nausea","Constipation","Dizziness","Hyperhidrosis"]}}